Welcome!

News Feed Item

Collaboration Results, Litigation Update, Market Activity, Earnings Release, and Clinical Trial Results - Research Reports on Aetna, Allergan, Valeant, Perrigo and Baxter

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, September 1, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Aetna Inc. (NYSE: AET), Allergan Inc. (AGN: AGN), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Perrigo Company Public Limited Company (NYSE: PRGO) and Baxter International Inc. (NYSE: BAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6107-100free.

--
Aetna Inc. Research Reports
On August 27, 2014, Aetna Inc. (Aetna) announced that its accountable care collaboration with Banner Health Network (BHN) has resulted in c.$5 million of shared savings on Aetna Whole Health fully-insured commercial membership in 2013 and also witnessed a 5% decline in average medical cost on the members. According to the Company, the collaboration also resulted in improved cancer screening rates, blood sugar management in diabetic members and reduced avoidable hospital admissions. Chuck Lehn, BHN's CEO said, "Aetna and BHN have a collaborative relationship that is to the benefit of our members and employers. These results are rewarding because they validate our model- it is possible to deliver quality care at more affordable prices." The full research reports on Aetna are available to download free of charge at:

http://www.analystsreview.com/Sep-01-2014/AET/report.pdf

--
Allergan Inc. Research Reports
On August 26, 2014, Allergan Inc. (Allergan) announced that it has requested the United States District Court for the Central District of California to set an expedited schedule for discovery and a motion for a preliminary injunction against Valeant Pharmaceuticals (Valeant), Pershing Square Capital Management, L.P. (Pershing Square), and its principal, William A. Ackman for violating federal securities laws. The Company also announced a Special Meeting of Stockholders to be held on December 18, 2014 in which shareholders of record at the close of business on October 27, 2014 will be entitled to vote. According to the Company, in its preliminary injunction movement, it will seek an order barring Valeant, Pershing Square, Mr. Ackman, and individuals affiliated with them from exercising any rights or benefits associated with Allergan shares that might have been acquired illegitimately and would prevent Valeant, Pershing Square, and Mr. Ackman from voting their shares in any special meeting. The full research reports on Allergan are available to download free of charge at:

http://www.analystsreview.com/Sep-01-2014/AGN/report.pdf

--
Valeant Pharmaceuticals International, Inc. Research Reports
On August 27, 2014, Valeant Pharmaceuticals International, Inc.'s (Valeant) stock declined 0.33% to end the trading session at $116.71. During the day, the stock opened at $118.25 and fluctuated within the range of $115.60 and $118.39, with a total of 1.35 million shares changing hands. Valeant's stock underperformed Dow Jones Industrial Average index which ended the session 0.09% higher. The full research reports on Valeant are available to download free of charge at:

http://www.analystsreview.com/Sep-01-2014/VRX/report.pdf

--
Perrigo Company Public Limited Company Research Reports
On August 14, 2014, Perrigo Company Public Limited Company (Perrigo) reported its Q4 FY 2014 and FY 2014 financial results (period ended June 28, 2014). The net sales for the quarter came in at $1.1 billion, up 18.3% YoY, mainly due to the new product sales of $65 million, $112 million attributable to the acquisition of Elan Corporation plc, and product acquisitions from Fera Pharmaceuticals, LLC and Aspen Global Inc. Net sales for FY 2014 came in at $4.1 billion, up 14.7% YoY, primarily led by $290 million in sales attributable to the Elan, Rosemont Pharmaceuticals, Ltd., Sergeant's Pet Care Products, Inc., Fera, Velcera Inc. and Aspen acquisitions and new product sales of $231 million. The net income for FY 2014 declined 53.5% YoY to $205.3 million, while net income for Q4 FY 2014 came in at $131.7 million, up 11.1% YoY. The Company expects diluted EPS for FY 2015 to range from $4.05 to $4.35 and net income to range from $546.1 million to $586.6 million. The full research reports on Perrigo are available to download free of charge at:

http://www.analystsreview.com/Sep-01-2014/PRGO/report.pdf

--
Baxter International Inc. Research Reports
On August 21, 2014, Baxter International Inc. (Baxter) announced encouraging results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)]. Top-line results from the study demonstrated that BAX 855 achieved its primary endpoint in the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or older. According to the Company, patients in a twice-weekly prophylaxis arm experienced a 95% reduction in median annualized bleed rates versus those in the on-demand arm. Baxter added that it anticipates submitting a Biologics License Application for BAX 855 to the U.S. Food and Drug Administration before 2014 year-end and will present additional data in the coming months. The full research reports on Baxter are available to download free of charge at:

http://www.analystsreview.com/Sep-01-2014/BAX/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


AnalystsReview.com

SOURCE Analysts Review

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"Space Monkey by Vivent Smart Home is a product that is a distributed cloud-based edge storage network. Vivent Smart Home, our parent company, is a smart home provider that places a lot of hard drives across homes in North America," explained JT Olds, Director of Engineering, and Brandon Crowfeather, Product Manager, at Vivint Smart Home, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events announced today that Conference Guru has been named “Media Sponsor” of the 22nd International Cloud Expo, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. A valuable conference experience generates new contacts, sales leads, potential strategic partners and potential investors; helps gather competitive intelligence and even provides inspiration for new products and services. Conference Guru works with conference organizers to pass great deals to gre...
DevOps is under attack because developers don’t want to mess with infrastructure. They will happily own their code into production, but want to use platforms instead of raw automation. That’s changing the landscape that we understand as DevOps with both architecture concepts (CloudNative) and process redefinition (SRE). Rob Hirschfeld’s recent work in Kubernetes operations has led to the conclusion that containers and related platforms have changed the way we should be thinking about DevOps and...
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and shared the must-have mindsets for removing complexity from the develop...
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, led attendees through the exciting evolution of the cloud. He looked at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering m...
The next XaaS is CICDaaS. Why? Because CICD saves developers a huge amount of time. CD is an especially great option for projects that require multiple and frequent contributions to be integrated. But… securing CICD best practices is an emerging, essential, yet little understood practice for DevOps teams and their Cloud Service Providers. The only way to get CICD to work in a highly secure environment takes collaboration, patience and persistence. Building CICD in the cloud requires rigorous ar...
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
"Evatronix provides design services to companies that need to integrate the IoT technology in their products but they don't necessarily have the expertise, knowledge and design team to do so," explained Adam Morawiec, VP of Business Development at Evatronix, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. In his session at @BigDataExpo, Jack Norris, Senior Vice President, Data and Applications at MapR Technologies, reviewed best practices to ...
Widespread fragmentation is stalling the growth of the IIoT and making it difficult for partners to work together. The number of software platforms, apps, hardware and connectivity standards is creating paralysis among businesses that are afraid of being locked into a solution. EdgeX Foundry is unifying the community around a common IoT edge framework and an ecosystem of interoperable components.
"ZeroStack is a startup in Silicon Valley. We're solving a very interesting problem around bringing public cloud convenience with private cloud control for enterprises and mid-size companies," explained Kamesh Pemmaraju, VP of Product Management at ZeroStack, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Large industrial manufacturing organizations are adopting the agile principles of cloud software companies. The industrial manufacturing development process has not scaled over time. Now that design CAD teams are geographically distributed, centralizing their work is key. With large multi-gigabyte projects, outdated tools have stifled industrial team agility, time-to-market milestones, and impacted P&L stakeholders.
"Akvelon is a software development company and we also provide consultancy services to folks who are looking to scale or accelerate their engineering roadmaps," explained Jeremiah Mothersell, Marketing Manager at Akvelon, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Enterprises are adopting Kubernetes to accelerate the development and the delivery of cloud-native applications. However, sharing a Kubernetes cluster between members of the same team can be challenging. And, sharing clusters across multiple teams is even harder. Kubernetes offers several constructs to help implement segmentation and isolation. However, these primitives can be complex to understand and apply. As a result, it’s becoming common for enterprises to end up with several clusters. Thi...
"Infoblox does DNS, DHCP and IP address management for not only enterprise networks but cloud networks as well. Customers are looking for a single platform that can extend not only in their private enterprise environment but private cloud, public cloud, tracking all the IP space and everything that is going on in that environment," explained Steve Salo, Principal Systems Engineer at Infoblox, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Conventio...